异甘草酸镁治疗慢性乙型肝炎重度患者外周血TregTh17细胞及其相关细胞因子水平变化*

doi:10.3969/j.issn.1672-5069.2020.06.009

摘要/Abstract

摘要： 目的探讨应用异甘草酸镁治疗慢性乙型肝炎(CHB)重度患者疗效及其外周血调节性T淋巴细胞和辅助性T细胞Th17(Treg/Th17)的变化。方法 2017年10月～2018年9月我科诊治的CHB重度患者80例,被分为观察组(n=50)和对照组(n=30),给予对照组护肝和抗病毒治疗,观察组则加用异甘草酸镁治疗,两组均治疗30天。结果在治疗30天末,观察组血清AST为(124.2±10.2)U/L,显著低于对照组[(179.3±13.5)U/L,P<0.05],ALT为(105.1±10.8)U/L,显著低于对照组[(135.6±14.8)U/L),P<0.05], TBIL为(34.8±4.8)μmol/L,显著低于对照组[(45.0±5.2)μmol/L),P<0.05];观察组血清TNF-α为(10.2±2.8)ng/L,显著低于对照组[(13.5±2.5)ng/L,P<0.05],IL-4为(49.1±7.2)ng/L,显著低于对照组[(62.2±6.2)ng/L,P<0.05],IL-10为(13.6±2.8)ng/L,显著低于对照组[(19.3±3.2)ng/L,P<0.05],而IL-2为(168.2±15.8)ng/L,显著高于对照组[(142.2±14.0)ng/L,P<0.05];观察组外周血Treg细胞为(3.1±0.4)%,显著低于对照组[(5.9±0.5)%,P<0.05],Th17细胞百分比为(3.2±0.4)%,显著低于对照组[(4.9±0.5)%,P<0.05],Treg/Th17细胞比值为(0.9±0.1)%,显著低于对照组[(1.2±0.3)%,P<0.05];观察组血CD4⁺为(42.2±4.3)%,显著高于对照组[(38.2±3.9)%,P<0.05],CD8⁺为(21.2±2.9)%,显著低于对照组[(26.2±2.2)%,P<0.05],CD4⁺/CD8⁺比值为(1.8±0.2),显著高于对照组[(1.6±0.5),P<0.05];观察组有45例(90.0%)患者病情好转,显著高于对照组的21例(70.0%),差异有统计学意义(P<0.05)。结论应用异甘草酸镁治疗慢性乙型肝炎重度患者效果明显,促进了肝功能恢复,改善了机体免疫功能紊乱,减轻了机体炎症反应。

关键词: 慢性乙型肝炎, 异甘草酸镁, 调节性T淋巴细胞, 辅助性T细胞Th17, T细胞亚群, 治疗

Abstract: Objective The aim of this study was to investigate the therapeutic effect of isoglycyrrhizic acid magnesium in the treatment of patients with severe chronic hepatitis B (CHB) and the changes of peripheral blood regulatory T lymphocytes (Treg) and helper T cell 17 (Th17). Methods 80 patients with CHB of severe degree in our hospital from October 2017 through September 2018, and were divided into observation (n = 50) and control group (n = 30). They were given liver protection and antiviral treatment, and those in the observation group were treated withisoglycyrrhizic acid magnesium at base of treatment in the control. The regimen lasted for 30 days. Results At the end of 30 days of treatment, serum AST in the observation group was (124.2±10.2) U/L, significantly lower than [(179.3±13.5) U/L, P<0.05], serum ALT was (105.1±10.8) U/L, significantly lower than [(135.6±14.8) U/L),P<0.05], serum bilirubin level was (34.8±4.8)μmol/L, significantly lower than [(45.0±5.2)μmol/L,P<0.05] in the control; serum TNF-α in the observation group was (10.2±2.8) ng/L, which was significantly lower than [(13.5±2.5) ng /L, P<0.05], and the IL-4 was (49.1±7.2) ng/L, significantly lower than [(62.2±6.2) ng/L, P<0.05], serum IL-10 was (13.6±2.8) ng / L, significantly lower than [(19.3±3.2) ng/L,P<0.05] ], while serum IL-2 was (168.2±15.8) ng/L, which was significantly higher than [(142.2±14.0) ng/L,P<0.05] in the control; in the observation group, the percentage of peripheral blood Treg cells were (3.1±0.4)%, which was significantly lower than [(5.9±0.5)%,P <0.05], and the percentage of Th17 cells was (3.2±0.4)%, which was significantly lower than [( 4.9±0.5)%, P<0.05], and the ratio of Treg / Th17 cells was (0.9±0.1)%, significantly lower than [(1.2±0.3)%, P<0.05] in the control; the peripheral blood CD4⁺ cells in the observation group was (42.2±4.3)%, significantly higher than [(38.2±3.9)%, P<0.05], the CD8 ⁺ was (21.2±2.9)%, significantly lower than [(26.2±2.2)%, P<0.05], and the CD4 ⁺ / CD8 ⁺ cell ratio was (1.8±0.2), significantly higher than [(1.6±0.5), P<0.05] in the control; 90.0% of patients in the observation group improved, which was significantly higher than 70.0% in the control group (P<0.05). Conclusion The application of isoglycyrrhizic acid magnesium in patients with severe chronic hepatitis B has obvious curative effects, which might promote liver function recovery and correct immune dysfunction.

Key words: Chronic hepatitis B, Isoglycyrrhizic acid magnesium, Regulatory T lymphocytes, Helper T cell 17, T cell subsets, Therapy

詹爱琴, 陈春丽, 朱庆峰, 李冰洁, 左维泽, 卢丽君. 异甘草酸镁治疗慢性乙型肝炎重度患者外周血TregTh17细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2020, 23(6): 793-796.

Zhan Aiqin, Chen Chunli, Zhu Qingfeng, et al. Therapeutic effect of isoglycyrrhizic acid magnesium in treatment of patients with hepatitis B and dynamic changes of Treg 17 cells and related cytokines[J]. Journal of Practical Hepatology, 2020, 23(6): 793-796.

参考文献

[1] 马贤庆,李剑霜,徐斌.芪灵合剂对慢性乙型肝炎患者Treg/Th17细胞平衡及相关细胞因子水平的影响.中国卫生检验杂志,2019,23(11):1021-1023.
[2] 柏文婕,石清兰,毛德文,等.柴芍六君汤对慢性乙型肝炎肝郁脾虚证患者肝纤维化相关指标改善作用以及血清Treg/Th17比值变化的影响.中国中医基础医学杂志,2019,23(8):1219-1221.
[3] 邱源旺,甘建和,杨文龙,等.Th1/Th2/Th17细胞因子在慢性乙型肝炎患者恩替卡韦停药后维持病毒学应答中的作用.中华实验和临床病毒学杂志,2018,32(1):43-47.
[4] 杨嘉,柯贵宝,胡耀,等.氯沙坦通过调节Treg/Th17细胞免疫平衡减轻慢性肾病小鼠动脉粥样硬化.中国医师杂志,2018,20(6):869-873,878.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[6] 丁俊琪.异甘草酸镁治疗慢性乙型肝炎及对患者Th1/Th2型细胞因子的影响.现代消化及介入诊疗,2016,21(4):542-545.
[7] 孙丽霞,徐国民.异甘草酸镁治疗难治性肾病综合征患者药物所致肝损伤的临床疗效.药物评价研究,2016,39(5):835-838.
[8] Kefalakes H, Koh C, Sidney J, et al. Hepatitis D virus-specific CD8₊ T cells have a memory-like phenotype associated with viral immune escape in patients with chronic hepatitis D virus infection.Gastroenterology,2019,156(6):1805-1819.
[9] 周炎仪,阳灿.雷公藤多甙片联合异甘草酸镁治疗自身免疫性肝炎患者疗效初步研究.实用肝脏病杂志,2019,22(3):101-103.
[10] 王新伟,杨道坤,梁海军.白细胞介素-35对慢性乙型肝炎患者外周血Th17细胞的影响及其临床意义.免疫学杂志, 2017,12(10):885-890.
[11] Malagnino V, Bottero J, Miailhes P, et al. Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.J Med Virol, 2019,91(4):630-641.
[12] 李红,王建红,郝彦琴,等.外周血辅助性T淋巴细胞17及其相关细胞因子在慢性乙型肝炎患者肠源性内毒素血症时的表达变化.中华传染病杂志,2016,34(9):563-565.
[13] Saito Y , Imamura M , Uchida T , et al. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. J Med Virol ,2020,92 (2 ):210-218.
[14] Pal S, Nandi M, Dey D, et al.Myeloid-derived suppressorcells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther, 2019,49(10):1346-1359.
[15] 史罗明,周根法.阿德福韦或恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者临床研究.实用肝脏病杂志,2018,21(1):54-57.
[16] Oladunni FS, Sarkar S, Reedy S, et al. Equid herpesvirus 1 targets the sensitization and induction steps to inhibit the type I interferon response in equine endothelial cells. J Virol, 2019,93(23): e01342-e01345.
[17] 王永力,吴文煜,尤洁,等.核苷(酸)类似物经治慢性乙型肝炎患者干扰素α治疗过程中细胞因子信号抑制因子3的表达与抗病毒疗效的关系.中华肝脏病杂志,2019, 27(1):27-32.
[18] Naganuma A,Sato K,Fukuchi T,et al. Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report. Clin J Gastroenterol,2019 ,12 (6 ):592-597.
[19] 雷静.利肝隆联合甘草酸二铵治疗自身免疫性肝炎患者疗效及其安全性研究.实用肝脏病杂志,2018,21(1):108-109.

异甘草酸镁治疗慢性乙型肝炎重度患者外周血TregTh17细胞及其相关细胞因子水平变化^*

Therapeutic effect of isoglycyrrhizic acid magnesium in treatment of patients with hepatitis B and dynamic changes of Treg 17 cells and related cytokines

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[2]	刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 7-9.
[3]	郑志恒, 李维筠, 回振宇, 陈莹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22.
[4]	吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.
[5]	林金祥, 杨可立. PEG-IFNα-2a与PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 27-30.
[6]	樊秉栋, 张国华, 王君. 索磷布韦/维帕他韦联合利巴韦林治疗慢性丙型肝炎患者疗效临床研究[J]. 实用肝脏病杂志, 2021, 24(1): 31-34.
[7]	杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.
[8]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[9]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[10]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[11]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[12]	蔡宇, 王孟春, 邱新平, 张宁宁, 刘丽莉, 吴博, 杨奇. 复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 71-74.
[13]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[14]	李庆玲, 何树光, 易小明, 段婷娜, 周意. 雷公藤多甙联合异甘草酸镁治疗自身免疫性肝炎患者外周血淋巴细胞PD-1和PD-L1变化[J]. 实用肝脏病杂志, 2021, 24(1): 79-82.
[15]	宋金云, 王建芳, 赵宏宇. 慢性乙型肝炎和肝硬化患者血清HBV基因型分析[J]. 实用肝脏病杂志, 2021, 24(1): 87-90.